Long-term follow up of alemtuzumab-treated patients: a retrospective study in a Belgian tertiary care center.

ATZ is a high efficacy therapy for active MS, providing long-term remission in a significant proportion of patients. Retreatment was more frequent in younger patients or patients having failed a higher number of previous DMTs.